Atopic Dermatitis (Q32 Bio Inc. Study)

Study Description

Brief Summary

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.

Condition or Disease

Atopic Dermatitis

Detailed Description

This is a two-part phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in adult subjects with persistent moderate to severe Atopic Dermatitis (AD). ADX-914 or matching placebo for administered subcutaneously in the clinic setting every 2 weeks for 12 weeks, and follow-up for 12 weeks. ADX-914 or matching placebo will be in the clinic setting post-randomization. In Part A, up to 3 cohorts of subjects will be randomized 2:1 drug vs placebo. In Part B subjects will be randomized 1:1 to drug vs placebo at a doses selected in Part A.

Study Design

Study Type:	Interventional (Clinical Trial)
Estimated Enrollment:	110 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Triple (Participant, Care Provider, Investigator)
Primary Purpose:	Treatment
Official Title:	A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis
Actual Study Start Date:	September 30, 2022
Estimated Primary Completion Date:	February 28, 2024
Estimated Study Completion Date:	May 30, 2024

Eligibility Criteria

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Inclusion Criteria

Age ≥18 years, inclusive, at time of informed consent, with chronic AD (duration of disease ≥3 years) diagnosed by the Eichenfield revised criteria of Hanifin and Rajka.
Moderate to severe disease activity at baseline and screening defined as:
- BSA affected ≥10%
- EASI Score ≥12
- Investigators Global Score (IGA) ≥3
Who, in the opinion of the Investigator, have a history of inadequate response to at least one of the following:
- at least 4-week course of medium-potency topical steroids or other approved topical immunomodulators (calcineurin, PDE-4 and JAK inhibitors)
- systemic steroids or phototherapy
- oral chemical synthetic immunomodulators (MTX, mycophenolate mofetil, azathioprine, cyclosporine, systemic approved biologics [dupliumab, ustekinumab or tralokinumab]), or approved systemic targeted synthetic JAK inhibitors (upadacitinib, abrocitinib)

Exclusion Criteria

Body weight ≤ 50.0 kg for men and ≤ 45.0 kg for women and > 100 kg at Screening
Rescue therapy, topical or systemic, need anticipated within 4 weeks of randomization
Recent (within 2 months of informed consent) or current clinically serious viral, bacterial, fungal, or parasitic infection or mycobacterial infection
A positive QuantiFERON®TB Gold test at Screening or history of tuberculosis (TB)
Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to receive a live vaccine during the study
Systemic, topical or device-based therapy of AD
Serious concomitant illness that could require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring
Other concomitant skin conditions that would interfere with evaluations of the effect of study medication on atopic dermatitis
Other active autoimmune diseases other than those above that would make it difficult to appropriately assess AD disease activity or pose a risk to the subject’s participation in the trial
Pregnant or lactating women, or women planning to become pregnant or initiate breastfeeding.
History of sensitivity to any of the study treatments, or components thereof, or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates their participation.
Has been in another investigational trial within 30 days or 5 half-lives of the investigational agent (whichever is greater) prior to the informed consent.

ADDITIONAL DETAILS

Application for Clinical Trials

Name(Required)

First Name Last Name

Phone(Required)

Email(Required)

Birthday(Required)

Select a State(Required)

Select a Condition (Arizona)(Required)

Select a Condition (Kansas)(Required)

Select a Condition (Maryland)(Required)

Select a Condition (Missouri)(Required)

Select a Condition (Texas)(Required)

Select a Clinical Trial: Actinic Keratosis (Arizona)(Required)

Select a Clinical Trial: Alopecia Areata (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Arizona)(Required)

Select a Clinical Trial: Atopic Dermatitis (Texas)(Required)

Select a Clinical Trial: Atopic Dermatitis (Maryland)(Required)

Select a Clinical Trial: Atopic Dermatitis (Missouri)(Required)

Select a Clinical Trial: Atopic Dermatitis (Kansas)(Required)

Select a Clinical Trial: Bullous Pemphigoid (Arizona)(Required)

Select a Clinical Trial: Hidradenitis Suppurativa (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Arizona)(Required)

Select a Clinical Trial: Prurigo Nodularis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Arizona)(Required)

Select a Clinical Trial: Psoriasis (Texas)(Required)

Select a Clinical Trial: Psoriasis (Maryland)(Required)

Select a Clinical Trial: Psoriasis (Missouri)(Required)

Select a Clinical Trial: Psoriasis (Kansas)(Required)

Select a Clinical Trial: Skincare (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Arizona)(Required)

Select a Clinical Trial: Skin Cancer (Missouri)(Required)

Select a Clinical Trial: Skin Cancer (Maryland)(Required)

How did you hear about us?(Required)

Message(Required)

CAPTCHA

This field is for validation purposes and should be left unchanged.

Menu

Study Description

Brief Summary

Condition or Disease

Detailed Description

Study Design

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Application for Clinical Trials

ACTIVE TRIALS

LOCATIONS

NAVIGATION

SOLUTIONS